Altria Group Inc (MO) Stock News

newcleo received a satisfactory safety opinion from French nuclear authority ASNR for its planned MOX fuel facility. The company has outgrown the France 2030 program scope due to significant capital raises and international expansion, including a planned NASDAQ listing via SPAC merger valuing it at $2.4 billion. France will continue supporting newcleo through licensing and regulatory assistance rather than direct funding.

Compass Therapeutics announced that its abstract for tovecimig, a DLL4 x VEGF-A bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will showcase Phase 2/3 COMPANION-002 trial results evaluating tovecimig combined with paclitaxel in patients with advanced biliary tract cancer, to be presented by Dr. Nilofer Azad from Johns Hopkins University on October 24, 2026.

Chevron to sign MOUs with Iraq for West Qurna 2 and Nassiriya oilfields  Reuters

Robbins Geller is seeking a lead plaintiff for a securities fraud class action lawsuit against Sportradar Group AG. The lawsuit alleges that Sportradar made false statements about its compliance practices and intentionally worked with black-market gambling operators. Following investigative reports published on April 22, 2026, Sportradar's stock fell over 22%. Investors with substantial losses have until July 17, 2026 to apply for lead plaintiff status.

A class action lawsuit has been filed against Veritone, Inc. for allegedly making false and misleading statements regarding revenue and cost recording. The company allegedly overstated revenue, assets, and accounts receivable due to deficient internal controls, requiring financial statement restatement. Investors who purchased Veritone securities between October 14, 2025 and April 14, 2026 have until July 20, 2026 to apply as lead plaintiff.

The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.

Mowi ASA achieved record-high Q2 2026 harvest volumes of 150 thousand tonnes, up 13% year-over-year from 133 thousand tonnes in Q2 2025. Operational EBIT grew 23% to EUR 231 million, with blending farming costs reduced by EUR 0.18/kg. The company also announced the divestment of its 9k GWT Canada East salmon farming operations to Cooke Inc. for CAD 225 million.

Japan Post Insurance and SCOR have signed a Memorandum of Understanding to establish a reinsurance vehicle for risk management. Under the agreement, Japan Post Insurance will cede underwriting risks from its Postal Life Insurance policies to SCOR, and both parties will invest in the reinsurance vehicle to achieve risk diversification benefits. The transaction is subject to final agreement and regulatory approvals.

NVRO Metals Limited has signed a non-binding memorandum of understanding with Hecla Mining Company to process approximately 35,000 tonnes of Hecla tailings at the NVRO Metals Hub in Australia's Northern Territory using the NVRO Process™. The agreement is conditional on successful completion of current test work on 20 tonnes of Hecla feedstock and completion of the Metals Hub acquisition by December 30, 2026. The MOU represents a milestone toward industrial-scale commercialization of NVRO's mineral processing technology.

VIEW Markets dive, Trump says Iran MOU 'is over'  Reuters

BMO has committed $500,000 over five years to expand the National Music Centre's Music Therapy Initiative across Canada. The investment, matched dollar-for-dollar by The Jim Pattison Foundation, will support evidence-based music therapy programs in hospitals and community health settings across multiple provinces, aiming to reach thousands of Canadians and improve patient outcomes through music therapy.

Vishay Intertechnology introduced four new 40 V TrenchFET Gen IV n-channel power MOSFETs (SIR5402DP, SIR5404DP, SIR5406DP, SIR5408DP) in PowerPAK SO-8 packages. These devices feature high minimum gate-source threshold voltage (>2.5 V) and optimized Qgd/Qgs ratios (<1) to prevent false triggering and reduce noise in motor control applications. The MOSFETs offer on-resistance values from 0.9 mΩ to 2.5 mΩ and are targeted at BLDC motors, power tools, drones, and automation systems.

Law firm Bragar Eagel & Squire is investigating MongoDB's board of directors for potential breach of fiduciary duties following significant stock price declines. MongoDB reported strong Q4 2023 results but issued lower-than-expected 2025 guidance in March 2024 due to changes in sales incentive structure, causing a $28.59 stock drop. In May 2024, further guidance cuts attributed to macro conditions resulted in a $73.94 per share decline. Long-term stockholders between August 31, 2023 and May 30, 2024 are encouraged to contact the firm.

A class action lawsuit has been filed against Graphic Packaging Holding Company for allegedly making false and misleading statements regarding inventory management issues, reduced demand, increased costs, and overstating business strength. The lawsuit covers securities purchased between February 4, 2025 and February 2, 2026. Investors have until July 6, 2026 to apply as lead plaintiff.

Polibeli Group Ltd. (NASDAQ: PLBL) has signed a non-binding Memorandum of Understanding with AUTHAIKAM COMPANY LIMITED to jointly evaluate a potential AI computing center project in Thailand with planned power capacity of up to 100 MW. The project is in early evaluation stage with no capital commitment made yet, subject to due diligence and regulatory approvals.

MEDIROM MOTHER Labs announced it received an additional order from Japan Ground Self-Defense Force's 8th Division for its REMONY® remote health monitoring system, tripling the initial deployment scale. The system utilizes the MOTHER Bracelet®, a recharge-free smart tracker that monitors vital health metrics continuously without requiring charging, making it suitable for harsh training environments and heatstroke prevention.

HUTCHMED announced positive Phase II pivotal trial results for fanregratinib (HMPL-453) in treating advanced intrahepatic cholangiocarcinoma patients with FGFR2 fusion/rearrangement. The study achieved a 42.5% objective response rate, 6.9-month median duration of response, and 16.6-month median overall survival, with a manageable safety profile. The company received priority review status from China's NMPA for a New Drug Application in December 2025.

Revolution Medicines announced it will present clinical data from four presentations at the 2026 ESMO Gastrointestinal Cancers Congress in Munich. The presentations include two oral presentations on zoldonrasib combination trials for RAS G12D metastatic pancreatic cancer and two Phase 3 trial-in-progress posters for daraxonrasib in first-line and adjuvant settings.

Two South Korean-operated vessels passed through Strait of Hormuz after MOU signed  Reuters

MOVA showcased its expanded residential energy storage portfolio at Intersolar Europe 2026, featuring the debut of the LumeGret S4800 plug-and-play system with up to 25kWh capacity and integrated EV charging. The company also officially launched the flagship A4000 model for sale and displayed the A2000 system, offering scalable solutions across different household sizes and applications.

The cell and gene therapy CDMO market is projected to grow from USD 8.3 billion in 2025 to USD 57.1 billion by 2034, driven by increasing clinical development of advanced therapies, rising outsourcing trends among biopharma companies, and technological advancements in manufacturing. North America leads the market with 40% share, while Asia-Pacific emerges as a significant growth hub. Key players are expanding manufacturing capabilities through strategic partnerships.

Allarity Therapeutics announced it will present a Trial-in-Progress poster on its Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen. The poster will outline the study design and clinical rationale for evaluating stenoparib, a dual PARP and WNT pathway inhibitor, in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The presentation will be led by Principal Investigator Dr. Kathleen N. Moore, a leading expert in gynecologic oncology.

Iran MOU was signed on Wednesday by Trump and Iran president, U.S. official says  Reuters

Iran's Baghaei says text of MOU has officially been signed by Iran and US  Reuters

MOUNT GILEAD, N.C. , June 15, 2026 /PRNewswire/ -- McRae Industries, Inc. (Pink Sheets: MCRAA and MCRAB) reported consolidated net revenues for the third quarter of fiscal 2026 of $27,418,000 as compared to $30,870,000 for the third quarter of fiscal 2025. Net earnings for the third quarter of fiscal 2026 amounted to $858,000, or $0.38 per diluted Class A common share, as compared to $3,160,000, or $1.40 per diluted Class A common share, for the third quarter of fiscal 2025. Consolidated net revenues for the first nine months of fiscal 2026 totaled $86,569,000 as compared to $87,120,000 for the first nine months of fiscal 2025. Net earnings for the first nine months of fiscal 2026 amounted to $3,262,000, or $1.45 per diluted Class A common share, as compared to net earnings of $6,059,000, or $2.68 per diluted Class A common share, for the first nine months of fiscal 2025. THIRD QUARTER FISCAL 2026 COMPARED TO THIRD QUARTER FISCAL 2025 Consolidated net revenues totaled $27.4 million for the third quarter of fiscal 2026 as compared to $30.9 million for the third quarter of fiscal 2025. Sales related to our western/lifestyle boot products for the third quarter of fiscal 2026 totaled $19.7 million as compared to $20.2 million for the third quarter of fiscal 2025. This decrease in net revenues was mainly driven by a decrease in our Laredo brand. Revenues from our work boot products decreased from $8.7 million for the third quarter of fiscal 2025 to $7.9 million for the third quarter of fiscal 2026. This was primarily a result of decreased orders on military boots. Additionally, third quarter revenues for fiscal 2025 included $2.0 million in land sales through our affiliate American Mortgage Investment Company (AMIC). Consolidated gross profit for the third quarter of fiscal 2026 amounted to approximately $6.9 million as compared to $9.8 million for the third quarter of fis

Mowi ASA held its Annual General Meeting on June 3, 2026, where all proposed agenda items were adopted. The company also successfully completed a placement of new senior unsecured green bonds, demonstrating continued access to capital markets and commitment to sustainable financing.

Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 78.6% in FRα-positive platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients. The drug demonstrated a favorable tolerability profile with median progression-free survival of 7.6 months across ovarian and endometrial cancer cohorts. Patient recruitment in dose optimization cohorts has been completed, supporting continued clinical development.

A class action lawsuit has been filed against Babcock & Wilcox Enterprises, Inc. for allegedly making false and misleading statements regarding a Power Generation Contract with Applied Digital. The lawsuit claims the company's largest shareholder BRC Group Holdings stood on both sides of the deal and that Applied Digital may not have actually needed the products/services, raising questions about revenue recognition and overstated business prospects. Investors who purchased B&W securities between November 5, 2025 and March 11, 2026 can apply to be lead plaintiff by June 15, 2026.

AIFU Inc. (NASDAQ:AIFU), a China-based AI-driven financial services platform, has signed a non-binding MOU to acquire Peakleap Ventures Limited, a company specializing in industrial AI solutions for waste recycling and resource recovery. The proposed acquisition aims to transform AIFU into a dual-engine business ecosystem combining 'Industrial AI + Digital Finance,' leveraging technologies in computer vision and predictive maintenance. The transaction remains subject to due diligence, definitive agreements, and regulatory approvals.

Nayax Ltd.'s Chief Marketing Officer Sever Michal exercised and sold 5,000 stock options for approximately $322,000, reducing direct holdings by 22.4%. The transaction reflects a liquidity event rather than a loss of confidence. The company, which provides cashless payment solutions for unattended retail, has seen strong performance with a 43.98% one-year price gain. Key metrics to watch include net retention stabilization above 115%, recurring revenue growth, and transaction value per device expansion.